Drugs / LODAPOLIMAB
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03495323 | May 2018 → Feb 2021 | cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT03343613 | Nov 2017 → Feb 2020 | non-small cell lung carcinoma, renal cell carcinoma, triple-negative breast carcinoma | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT03099109 | Apr 2017 → Dec 2019 | neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02791334 | Jun 2016 → May 2020 | cutaneous melanoma, hormone receptor-positive breast cancer, malignant pancreatic neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02937272 Background | Nov 2016 → Feb 2020 overdue | cancer | Eli Lilly and Company | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LODAPOLIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298020 ↗ |
| Known as | LY3300054 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02791334 ↗ |
| Action | Inhibit | “a new programmed cell death ligand 1 (PD-L1) inhibitor, LY3300054” PMID 33229456 ↗ Nov 2020 |
| Modality | Monoclonal antibody | “LY3300054 is a monoclonal antibody that targets programmed cell death ligand 1 (PD-L1).” NCT03495323 ↗ |
| Route | Intravenous | “LY3300054 given intravenously (IV) on day 1 and day 15 of a 28 day cycle” NCT02791334 ↗ |
| Target | CD274 | “LY3300054 is a monoclonal antibody that targets programmed cell death ligand 1 (PD-L1).” NCT03495323 ↗ |